Early Access Program for ALXN1840 in Patients With Wilson Disease

Status No longer available

Clinical Trial Summary

This is an open-label, single-arm, multi-center EAP, designed to provide early access to ALXN1840 for eligible patients with WD.

Clinical Trial Description

To provide access to ALXN1840 treatment, an investigational medicinal product (IMP) that has not yet been granted marketing authorization, to participants who complete Studies ALXN1840-WD-205, WTX101-301, or ALXN1840-WD-302, or other studies with ALXN1840 who, in the opinion of the Treating Physician, may benefit from continued treatment with ALXN1840, and who meet the eligibility criteria described in this protocol. ;

Study Design

Related Conditions & MeSH terms

Wilson Disease

Clinical Trial Details

NCT number	NCT05686564
Study type	Expanded Access
Source	Alexion
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04573309` - Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840	Phase 2
Completed	`NCT03539952` - Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease	Phase 3
Active, not recruiting	`NCT04884815` - Study of UX701 Gene Transfer for the Treatment of Wilson Disease	Phase 1/Phase 2
Not yet recruiting	`NCT03659331` - A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease	N/A
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT04965571` - Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
Terminated	`NCT05047523` - Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease	Phase 3
Completed	`NCT04526210` - Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	Phase 1
Completed	`NCT00004338` - Study of Zinc for Wilson Disease	Phase 4
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT02273596` - Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients	Phase 2
Completed	`NCT02763215` - The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
Recruiting	`NCT05444127` - Oral Health and Wilson's Disease: SOMAWI
Completed	`NCT04408300` - Study of Retinal Vascular Parameters in Patients With Wilson's Disease	N/A
Active, not recruiting	`NCT05783687` - Real World Evidence Study in Subjects With Wilson's Disease
Terminated	`NCT04909346` - Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
Completed	`NCT03867526` - Establishment of Human Cellular Disease Models for Wilson Disease
Enrolling by invitation	`NCT03589820` - Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure	N/A
Completed	`NCT04526197` - Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.	Phase 1
Not yet recruiting	`NCT06430359` - Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients